Report Highlights

U.S. Nitric Oxide Test Market Overview

The U.S. nitric oxide test market reached USD 265 million in 2024 and is projected to reach USD 510 million by 2032 at an 8.5% CAGR, driven by the expanding clinical role of fractional exhaled nitric oxide measurement in asthma diagnosis, anti-inflammatory therapy guidance, and biologic treatment selection and monitoring. FeNO — measured using handheld or desktop electrochemical detection devices that analyse exhaled breath samples — provides a non-invasive, real-time marker of eosinophilic airway inflammation that complements spirometry and symptom-based asthma assessment by directly measuring the type-2 inflammatory pathway that is the primary target of modern biologic asthma therapies. The U.S. market's growth is anchored by the 25 million Americans with asthma — of whom an estimated 3.6 million have severe asthma meeting biologic therapy criteria — and the increasing emphasis on precision medicine approaches to asthma management that use biomarkers including FeNO to match patients to the anti-inflammatory treatment most likely to provide clinical benefit.

The competitive landscape is served by two primary FeNO measurement platforms — NIOX (Circassia) and NObreath (Bedfont Scientific) — that hold the majority of installed device positions in U.S. pulmonology, allergy, and respiratory medicine practices, supplemented by academic centre spirometry laboratories and respiratory function testing facilities that have integrated FeNO measurement into their pulmonary function testing programmes. The market also includes hospital-based exhaled NO monitoring for neonatal care and paediatric pulmonology applications where nitric oxide measurement serves a different clinical purpose — inhaled nitric oxide therapy monitoring for neonatal hypoxic respiratory failure — that creates a distinct clinical application segment from the outpatient asthma management market that drives the primary FeNO testing volume.

Growth Drivers for U.S. Nitric Oxide Test Market

Three demand drivers sustain the U.S. nitric oxide test market through 2032. The precision asthma medicine transition — where eosinophilic asthma phenotyping through FeNO, blood eosinophil count, and periostin measurement is becoming standard practice for biologic therapy candidate selection — is creating structured diagnostic testing demand in pulmonology and allergy practices that previously managed asthma without biomarker-guided treatment selection. FDA approval of biologics requiring type-2 inflammatory status confirmation — dupilumab's 2021 approval for moderate-to-severe eosinophilic asthma, tezepelumab's 2022 approval spanning multiple asthma phenotypes — has created a clinical workflow need for rapid, in-office FeNO assessment that avoids the 2–3 week turnaround of centralised laboratory eosinophil panel testing when treatment decision timing is clinically urgent.

Paediatric asthma diagnosis presents a specific growth opportunity where FeNO's non-invasive measurement approach — requiring only a controlled exhalation effort rather than the spirometric forced vital capacity manoeuvre that young children frequently cannot perform correctly — provides diagnostic information accessible in children as young as 4–5 years who are unable to reliably perform conventional spirometry. Paediatric pulmonology and paediatric allergy practices that have adopted FeNO report improved diagnostic confidence in early childhood asthma evaluation, and the growing paediatric asthma prevalence — affecting an estimated 6.5 million U.S. children — creates a large paediatric testing market that FeNO devices are positioned to serve as their paediatric reference range data and clinical validation evidence bases expand. The digital health integration opportunity — where FeNO measurement is integrated with electronic health record systems, patient monitoring apps, and telemedicine platforms to enable remote asthma management with objective inflammatory monitoring — is creating a connected device revenue model that supplements single-device sales with data subscription and software maintenance revenue.

Regulatory and Reimbursement Environment

The U.S. nitric oxide test market regulatory framework is administered through FDA's device oversight for FeNO measurement devices — which are cleared as Class II 510(k) devices under product code QMX for exhaled nitric oxide measurement systems. Circassia's NIOX VERO and Bedfont Scientific's NObreath both hold FDA 510(k) clearances for exhaled nitric oxide measurement in asthma management, providing the regulatory foundation for Medicare Part B reimbursement through the durable medical equipment or physician office testing frameworks. FeNO testing reimbursement under Medicare Part B is established at USD 53–65 per test under CPT code 95012 (nitric oxide expired gas determination), with the rate reflecting the relative work value assigned through the American Medical Association RVS Update Committee process. The CPT code's existing rate has been a limiting factor in primary care FeNO adoption, as the USD 53–65 reimbursement rate is below the threshold at which the device amortisation economics for low-volume primary care practices justify FeNO investment relative to the diagnostic value the test provides to the referring specialist who manages the patient's asthma therapy.

The most commercially significant reimbursement development for the U.S. FeNO market is the potential coding and reimbursement update that would reflect FeNO's clinical value in biologic therapy selection — specifically its role in identifying the highest-responding patient subgroups for biologics whose annual per-patient cost exceeds USD 20,000. Health economic analyses demonstrating that FeNO-guided biologic selection reduces the number of biologic trial failures — each representing USD 20,000-plus in ineffective therapy costs — provide a compelling total cost of care argument for elevated FeNO reimbursement rates that payers motivated to optimise biologic therapy spend efficiency are beginning to consider in value-based benefit design discussions with pulmonology and allergy specialty medical societies.

Market Opportunities in U.S. Nitric Oxide Test Market

The chronic rhinosinusitis and nasal polyp management opportunity represents a growing FeNO application adjacency, as the FDA approvals of dupilumab, omalizumab, and mepolizumab for chronic rhinosinusitis with nasal polyps — conditions with overlapping type-2 inflammatory pathophysiology with asthma — creates biologic therapy patient selection demand in otolaryngology and rhinology practices that are less familiar with FeNO testing than pulmonology and allergy practices but are managing a patient population whose biologic therapy decisions benefit from type-2 inflammatory biomarker guidance. FeNO device manufacturers who develop clinical education programmes for otolaryngology and rhinology practices — specifically addressing the FeNO test's utility in CRS-NP biologic candidate identification where blood eosinophil count alone may be insufficiently specific — are accessing a commercial channel with lower competitive density than the pulmonology and allergy practices that FeNO vendors have historically targeted.

The home FeNO monitoring opportunity is emerging as digital respiratory health monitoring expands through connected health device adoption. Circassia's development of consumer-accessible FeNO monitoring formats — building on the clinical validation of the NIOX platform — and FDA's receptiveness to digital health device clearances for chronic disease management are creating a regulatory pathway for patient-operated home FeNO monitoring that would enable asthma patients to track their own airway inflammation trends between clinic visits. Home FeNO monitoring that integrates with physician-accessible data platforms would enable proactive therapy adjustment before symptomatic deterioration — a clinical model that aligns with value-based care objectives and creates a subscription-based revenue model for FeNO device manufacturers that generates recurring revenue per patient enrolled in monitoring programmes rather than per-device sale economics.

Market at a Glance

Leading Market Participants

• Circassia (NIOX)
• Bedfont Scientific (NObreath)
• Aerocrine (acquired by Circassia)
• eco Medics AG
• Spirent Medical
• Vyaire Medical
• ndd Medical Technologies
• MGC Diagnostics
• CareFusion (BD)
• Vitalograph

Competitive Outlook for U.S. Nitric Oxide Test Market

The U.S. nitric oxide test market will reach USD 510 million by 2032, with the competitive landscape expanding from its current pulmonology and allergy focus into otolaryngology, paediatric medicine, and digital health monitoring channels as the clinical evidence base for FeNO across multiple type-2 inflammatory indications matures and device platform connectivity enables home and remote monitoring applications. The biologic therapy companion testing positioning will be the most commercially impactful strategic development — as FeNO's role in identifying the highest-responding biologic therapy candidate subgroups becomes embedded in pulmonology and allergy practice workflows through specialty society guideline updates and biologic manufacturer prescribing support programmes, FeNO testing volume in specialist practices will grow proportionally to the biologic therapy prescribing volume growth that is projected at 12–15% annually through 2030.

The most commercially disruptive development would be approval of a consumer-accessible home FeNO monitoring device that enables asthma patients to self-monitor airway inflammation trends — a development that would transform FeNO from a clinic-based procedure generating per-visit revenue into a continuous monitoring platform generating subscription-based recurring revenue per patient enrolled. The home monitoring model's revenue per patient lifetime value significantly exceeds the clinic-based per-test model, making home FeNO monitoring the strategic growth investment that will define the commercial architecture of the U.S. FeNO market's second decade of growth beyond the 2032 forecast horizon.